Table 3. Multivariable analysis for prognostic factors for RFS, PFS and CSS.
| Variable | Recurrence-free survival | Progression-free survival | Cancer-specific survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | |||
| CIS concomitant (ref) | 0.211 | – | – | 0.431 | – | – | 0.241 | – | – | ||
| Primary | 0.214 | 1.39 | 0.83–2.34 | 0.212 | 1.53 | 0.76–2.99 | 0.099 | 2.27 | 0.87–5.95 | ||
| Secondary | 0.247 | 0.98 | 0.54–1.79 | 0.258 | 1.52 | 0.75–3.13 | 0.243 | 1.86 | 0.66–5.24 | ||
| Age | 0.099 | 0.98 | 0.96–1.00 | 0.155 | 0.98 | 0.96–1.00 | 0.386 | 1.02 | 0.98–1.05 | ||
| Gender (female vs. male) | 0.037 | 1.82 | 1.04–3.19 | 0.075 | 1.88 | 0.94–3.78 | 0.432 | 1.47 | 0.57–3.74 | ||
| Instillation number | 0 | 0.92 | 0.89–0.95 | 0 | 0.89 | 0.87–0.93 | 0 | 0.89 | 0.85–0.93 | ||
The value of adjusted P<0.05 was considered statistically significant. HR, Hazard ratio; 95% CI, 95% confidence interval; CIS, carcinoma in situ; HR >1 worse outcome for the bolded option, HR <1 better outcome for the bolded option.